NCT04520321View on ClinicalTrials.gov

A Phase 1/ Phase 2 Study of TTHX1114(NM141)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 19, 2020

Primary Completion Date

April 23, 2021

Study Completion Date

May 18, 2021

Conditions
Corneal Endothelial DystrophyFuchs Endothelial Corneal DystrophyPseudophakic Bullous KeratopathyEndothelial Dysfunction
Interventions
DRUG

TTHX1114(NM141)

engineered FGF-1 delivered intracamerally

OTHER

Vehicle (placebo)

Placebo

Trial Locations (8)

12603

Alterman, Modi and Wolter, Poughkeepsie

32204

Levenson Eye Associates, Inc, Jacksonville

46260

Price Vision Group, Indianapolis

57108

Vance Thompson Vision - Sioux Falls, Sioux Falls

60169

Chicago Corneal Consultants, Hoffman Estates

64111

Tauber Eye Center, Kansas City

68137

Vance Thompson Vision - Omaha, Omaha

94954

North Bay Eye Associates, Inc., Petaluma

All Listed Sponsors
lead

Trefoil Therapeutics, Inc.

INDUSTRY

NCT04520321 - A Phase 1/ Phase 2 Study of TTHX1114(NM141) | Biotech Hunter | Biotech Hunter